DiscGenics Company Update
We officially commenced clinical evaluation of IDCT for degenerative disc disease last month, and just yesterday, announced the first patient has been treated in our U.S. Phase I/II trial. […]
We officially commenced clinical evaluation of IDCT for degenerative disc disease last month, and just yesterday, announced the first patient has been treated in our U.S. Phase I/II trial. […]
SALT LAKE CITY–(BUSINESS WIRE)–Utah life sciences companies, and BioUtah members, ProLung, Inc., and Rosivo Inc., were among ten innovative companies announced as winners in the 16th annual Utah Innovation Awards, presented by Stoel Rives, LLP, and the Utah Technology Council. Winners were honored during a special awards dinner, April 26, at the Hilton Salt Lake […]
On April 22, the Daily Herald published an article highlighting Tolero Pharmaceuticals’ research in “personalized medicine.” This concept is based on the idea that drugs can be more effective once doctors know whether or not they will be right for specific patients. “It’s the right drug for the right patient for the right disease,” said Kelly Slone, president […]
Jim Greenwood, CEO of BIO, acknowledges Senator Hatch for his groundbreaking work in biotechnology policy following his honors at BIO’s 25 Years of Innovation this month. […]